Home / Journals / OR / Vol.29, No.3, 2021
Special Issues
Table of Content
  • Open AccessOpen Access

    ARTICLE

    Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells

    MESFER AL SHAHRANI1,2,*, PRASANNA RAJAGOPALAN1,2, MOHAMMAD ABOHASSAN1, MOHAMMAD ALSHAHRANI1, YASSER ALRAEY1, REEM M. GAHTANI1, SURESH RADHAKRISHNAN3, KHLOOD DAGREERY4
    Oncology Research, Vol.29, No.3, pp. 149-157, 2021, DOI:10.32604/or.2022.03539 - 01 August 2022
    Abstract Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6- methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance (1 H-NMR), 13C-NMR, and mass spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were… More >

  • Open AccessOpen Access

    ARTICLE

    RNF43 is a novel tumor-suppressor and prognostic indicator in clear cell renal cell carcinoma

    DAWEI ZHU1,#, LEI ZHANG1,#, XIAOKAI SHI1, SHENGLIN GAO1, CHUANG YUE1, LIFENG ZHANG1, YU BAI1, QIFENG WANG2, ATSUSHI OKADA3, TAKAHIRO YASUI3, CHAO WANG1,4, XINGANG CUI4,5,*, LI ZUO1,*
    Oncology Research, Vol.29, No.3, pp. 159-174, 2021, DOI:10.32604/or.2022.03458 - 01 August 2022
    Abstract Identifying prognostic indicators of clear cell renal cell carcinoma (ccRCC) and elucidating the mechanisms underlying ccRCC progression are crucial for improving ccRCC patient prognosis. This study investigated the clinical significance and biological role of Ring finger protein 43 (RNF43) in ccRCC. Two independent cohorts of patients with ccRCC were employed to determine the prognostic significance of RNF43 by immunohistochemistry and statistical analyses. In vitro and in vivo experiments, RNA-seq, and other techniques were used to determine the biological role of RNF43 in ccRCC and related molecular mechanisms. RNF43 expression was commonly decreased in ccRCC specimens, and low… More >

  • Open AccessOpen Access

    ARTICLE

    Long noncoding RNA LINC01124 activates hepatocellular carcinoma cell proliferation, migration, and invasion by absorbing microRNA-1247-5p and overexpressing FOXO3

    LEI SUN1,2, YUE ZHANG3, YUQIN YAO4, HONGLIN DU3, YUEHUA ZHANG1, AIPING FANG1,2,*
    Oncology Research, Vol.29, No.3, pp. 175-187, 2021, DOI:10.32604/or.2022.03550 - 01 August 2022
    Abstract Long intergenic non-protein coding RNA 1124 (LINC01124) has been identified as an important regulator of non-small-cell lung cancer. However, the expression and detailed role of LINC01124 in hepatocellular carcinoma (HCC) remain unestablished to date. Therefore, this study aimed to elucidate the role of LINC01124 in the aggressiveness of HCC cells and identify the underlying regulatory mechanism. Quantitative reverse transcriptase-polymerase chain reaction was performed to measure the expression of LINC01124 in HCC. Cell Counting Kit-8 assay, Transwell cell migration and invasion assays, and a xenograft tumor model were used to investigate the function of LINC01124 in… More >

  • Open AccessOpen Access

    ARTICLE

    Long noncoding RNA CCDC183-AS1 depletion represses breast cancer cell proliferation, colony formation, and motility by sponging microRNA-3918

    TAO LIU1, LIMIN ZHOU1, LIANBO ZHANG2, XIN GUAN3, YI DONG1,*
    Oncology Research, Vol.29, No.3, pp. 189-200, 2021, DOI:10.32604/or.2022.03573 - 01 August 2022
    Abstract Many studies have illustrated the significance of long noncoding RNAs in oncogenesis and promotion of breast cancer (BC). However, the biological roles of CCDC183 antisense RNA 1 (CCDC183-AS1) in BC have rarely been characterized. Thus, we explored whether CCDC183-AS1 is involved in the malignancy of BC and elucidated the possible underlying mechanisms. Our data confirmed elevated CCDC183-AS1 expression in BC, which was associated with poor clinical outcomes. Functionally, knocking down CCDC183-AS1 hampered cell proliferation, colony formation, migration, and invasion in BC. Additionally, the absence of CCDC183-AS1 restrained tumor growth in vivo. Mechanistically, CCDC183-AS1 executed as a More >

  • Open AccessOpen Access

    ARTICLE

    The LncRNA FEZF1-AS1 promotes tumor proliferation in colon cancer by regulating the mitochondrial protein PCK2

    HUAMIN WANG1,#, YANTING WU1,#, ZHENLEI WANG2,#, YUHANG CHEN1, JINYU MO1, WEN GUAN1, YALI ZHANG1, HONGLIANG YAO1,*
    Oncology Research, Vol.29, No.3, pp. 201-215, 2021, DOI:10.32604/or.2022.03553 - 01 August 2022
    Abstract LncRNAs and metabolism represents two factors involved in cancer initiation and progression. However, the interaction between lncRNAs and metabolism remains to be fully explored. In this study, lncRNA FEZF1-AS1 (FEZF1- AS1) was found upregulated in colon cancer after screening all the lncRNAs of colon cancer tissues deposited in TCGA, the result of which was further confirmed by RNAscope staining on a colon tissue chip. The results obtained using FEZF1- AS1 knockout colon cancer cells (SW480 KO and HCT-116 KO) constructed using CRISPR/Cas9 system confirmed the proliferation, invasion, and migration-promoting function of FEZF1-AS1 in vitro. Mechanistically, FEZF1-AS1… More >

  • Open AccessOpen Access

    ARTICLE

    Computational docking and in vitro analysis identifies novel arylidene analogue FPMXY-14 against renal cancer cells by attenuating Akt

    HASSAN M. OTIFI1, MISHARI ALSHYARBA2, MAJED AL FAYI3,4, AYED A. DERA3,4, PRASANNA RAJAGOPALAN3,4,*
    Oncology Research, Vol.29, No.3, pp. 217-227, 2021, DOI:10.32604/or.2022.03570 - 01 August 2022
    Abstract Targeted therapies are gaining global attention to tackle Renal Cancer (RC). This study aims to screen FPMXY- 14 (novel arylidene analogue) for Akt inhibition by computational and in vitro methods. FPMXY-14 was subjected to proton NMR analysis and Mass spectrum analysis. Vero, HEK-293, Caki-1, and A498 cell lines were used. Akt enzyme inhibition was studied with the fluorescent-based kit assay. Modeller 9.19, Schrodinger 2018-1, LigPrep module, and Glide docking were used in computational analysis. The nuclear status was assessed by PI/Hoechst- 333258 staining, cell cycle, and apoptosis assays were performed using flow cytometry. Scratch wound and… More >

Per Page:

Share Link